CANY
NVCR icon

Caxton Associates (New York)’s NovoCure NVCR Stock Holding History

Caxton Associates (New York)’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,087
Closed -$747K – 578
2020
Q1 		$747K Buy
11,087
+7,543
+213% +$596K 0.14% 91
2019
Q4 		$299K Buy
+3,544
New +$286K 0.04% 279
2019
Q3 		– Sell
-5,064
Closed -$320K – 495
2019
Q2 		$320K Sell
5,064
-736
-13% -$37.3K 0.04% 271
2019
Q1 		$279K Buy
+5,800
New +$279K 0.04% 276

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Caxton Associates (New York)'s NVCR Position: Q2 2020 in Review

Caxton Associates (New York) sold out of NovoCure (NVCR) in Q2 2020, closing a stake of 11,087 shares — an estimated $747K sold.

Caxton Associates (New York) first reported a position in NVCR in Q1 2019 and held it in 4 quarters. The position peaked at $747K in Q1 2020. 264 funds tracked by Wall St. Rank hold NVCR as of Q2 2020.

  • Caxton Associates (New York) reported no remaining NovoCure position as of Q2 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 11,087 NovoCure shares in Q2 2020, an estimated $747K.
  • Caxton Associates (New York) first reported a position in NovoCure in Q1 2019 and held it in 4 quarters.
  • Caxton Associates (New York)'s NovoCure position peaked at $747K in Q1 2020.
  • 264 funds tracked by Wall St. Rank held NovoCure as of Q2 2020.

Based on Caxton Associates (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.